MAIA Biotechnology (MAIA) AGM 2026 summary
Event summary combining transcript, slides, and related documents.
AGM 2026 summary
22 May, 2026Opening remarks and agenda
Meeting called to order and chaired by Vlad Vitoc, welcoming shareholders and outlining virtual voting procedures.
Business portion conducted first, followed by a Q&A session at the end.
Board and executive committee updates
Attendance included independent board members, executive management, legal counsel, accountants, and representatives from Broadridge Financial Solutions.
Adelina Louie Ngar Yee (Audit and Nominating/Corporate Governance Chair) and Stan V. Smith (Compensation Chair) highlighted.
Shareholder proposals
Election of Adelina Louie Ngar Yee and Steven M. Chaouki as Class I directors for a three-year term proposed and nominated.
Ratification of Grant Thornton LLP as independent auditors for fiscal year ending December 31, 2026, proposed.
Latest events from MAIA Biotechnology
- Ateganosine (THIO) delivers unprecedented efficacy in late-stage cancer trials, targeting major global markets.MAIA
Investor presentation - Advanced Phase 3 NSCLC trial, raised $33M, and reported a $14.3M net loss for H1 2026.MAIA
Q2 2026 - Disclosure updates compensation to the CEO's brother and confirms proxy voting procedures.MAIA
Proxy filing - $33M equity raise boosts cash to $34.4M, funding Phase 3 NSCLC trial; net loss rises to $6.37M.MAIA
Q1 2026 - Proxy statement amended to disclose equity compensation plan details and available shares.MAIA
Proxy filing - Election of directors and auditor ratification headline the 2026 virtual annual meeting.MAIA
Proxy filing - Virtual meeting to elect directors and ratify auditor, with strong governance and director alignment.MAIA
Proxy filing - Advanced clinical pipeline and $33M capital raise position company for pivotal 2026 milestones.MAIA
Q4 2025 - THIO's pivotal trials show high efficacy in cancer, with major milestones and approvals expected by 2026.MAIA
Biotech Showcase 2025 Investor Conference